Toxemia of pregnancy and DIC
スポンサーリンク
概要
- 論文の詳細を見る
To investigate relationship between toxemia of pregnancy and DIC, coagulation tests were performed with reference to Gestosis Index, which indicates the severty of toxemia of pregnancy.Subjects consisted of 24 patients with toxemia of pregnancy in the 3rd trimester, and 73 control women who were non-pregnant or in the 3rd trimester of normal pregnancy.1) Bleeding time (min) was 2.8±1.1 in non-pregnancy, 3.3±0.8 in normal pregnancy, and 5.5±1.7 in toxemia of pregnancy.2) Blood clotting time (min) was 9.9±1.8, 8.6±2.8, and 9.4±2.1, respectively.3) Platelet count (×104/mm3) was 37.1±7.84, 25.1±6.91 and 22.0±4.77, and fibrinogen content (mg/dl) 327.0±103.3, 408.0±46.9 and 348.3±66.3, respectively.4) Serum FDP was 18.5±13.4μg/ml and urine FDP was 0.63±0.73μg/ml in toxemia of pregnancy.5) BSR (mm/1hr) was 9.6±4.8 in non-pregnancy, 42.2±11.4 in normal pregnancy, and 43.3±14.4 in toxemia of pregnancy.6) Plasma factor XIII evaluated by spot method (μM-MDH/10min) was 18.0±3.85 in non-pregnancy, 14.1±3.45 in normal pregnancy, and 9.45±1.85 in toxemia of pregnancy. According to Laurell's method (%), its subunit A was 80.0±2.93 in non-pregnancy, 67.0±17.0 in normal pregnancy, and 51.1±9.75 in toxemia of pregnancy, while its subunit S was 79.0±10.4, 109.0±23.3 and 84.3±16.8, respectively.7) No marked change was seen in PT or APTT.8) Platelet ADP aggregation (%) was 49.7±10.5 in non-pregnancy, 53.2±10.6 in normal pregnancy, and 82.2±7.9 in toxemia of pregnancy.9) Platelet spreadability (μ) was 7.88±0.29, 7.83±0.21 and 9.76±0.16, respectively.10) A good correlation was found between Gestosis Index and blood clotting time, platelet count, fibrinogen content or serum FDP.The aforesaid findings suggest that the severity of toxemia of pregnancy is correlated to chronic DIC.
- 一般社団法人 日本血栓止血学会の論文
一般社団法人 日本血栓止血学会 | 論文
- 日本人のＡＤＡＭＴＳ１３
- Infection of specific strains of Streptococcus mutans exacerbated intracerebral hemorrhage
- Transcriptional regulation of megakaryopoiesis and thrombopoiesis
- 新規血小板活性化受容体ＣＬＥＣ－２ その発見から今後の展望まで:その発見から今後の展望まで
- １．臨床血栓止血学オーバービュー